Contact

Gene Therapy in Parkinson's Disease

Ph Hantraye’ Conference at the Mediatheque of Fontenay aux Roses 

Read more...

Memory and epilepsy: the role of connexin 30

Memory and epilepsy: the role of connexin 30

CEA-I2BM shows that connexin 30 is a new potential therapeutic target to increase memory or reduce seizures in patients with epilepsy.

"Connexin 30 sets synaptic strength by controlling astroglial invasion synapse" in Nature Neurosciences

Click here to learn more

Parkinson's disease: a breakthrough thanks to gene therapy

Parkinson's disease: a breakthrough thanks to gene therapy

A Franco-British team (AP-HP, INSERM, UPEC, CEA / MIRCen, Oxford Biomedica, Cambridge University) conducted a Phase I-II gene therapy clinical trial in patients with an advanced form of Parkinson’s disease.

Click here to learn more

MIRCen acquired a new Magnetic resonance imaging (MRI) scanner (11,7 Teslas) dedicated to rodents

MIRCen, preclinical research platform on neurodegenerative diseases located in Fontenay-aux-Roses, has just acquired a new Magnetic resonance imaging (MRI) scanner dedicated to rodents.

 

Read more...